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Background: The aim of this study is to compare clinical outcomes between patients with solitary lymph node
metastasis and node-negative (N0) patients in squamous cell carcinoma of the middle thoracic esophagus.
Methods: A series of 135 patients with squamous cell carcinoma of the middle thoracic esophagus were
retrospectively investigated. There were 33 patients with solitary lymph node metastasis and 102 N0 patients. Skip
metastasis in 33 patients with solitary lymph node metastasis was defined according to three criteria: Japanese
Society for Esophageal Disease (JSED), American Joint Commission on Cancer (AJCC), and the anatomical
compartment.
Results: In 33 patients with solitary lymph node metastasis, skip metastasis was shown in 13, 23, and 8 patients
according JSED, AJCC and anatomical compartment respectively. The 5-year survival rates for N0 patients and
patients with solitary lymph node metastasis were 58% and 32% respectively (P =0.008). Multivariate analysis
revealed that skip metastasis was not an independent prognostic factor.
Conclusions: For patients with middle thoracic esophageal squamous cell carcinoma, solitary lymph node
metastasis has a negative impact on survival compared with N0 disease; skip metastasis, however, is comparable to
N0 diseases in predicting prognosis.
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Middle thoracic esophageal squamous cell carcinoma is
characterized by a bidirectional lymphatic spread and
lymph node metastasis [1,2]. Lymphadenectomy is an
important component of surgical procedures aiming for
complete resection of lesions for patients with esopha-
geal carcinoma. The sentinel lymph node concept for
lymphadenectomy has recently been developed in order
to individualize the indication for lymphadenectomy and
therefore to reduce the surgical stress of thoracic
esophageal carcinoma surgery [3]. However, this concept
is questioned by some authors [4-6]. For example, the
site of solitary lymph node metastasis, which is thought
to be the site of initial lymph node metastasis, is difficult* Correspondence: lsteng@zju.edu.cn
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reproduction in any medium, provided the orto predict in esophageal carcinoma because the location
of solitary lymph node metastasis is extensively distribu-
ted in the neck, mediastinum, and upper abdomen [4-6].
Similarly, metastasis to anatomically distant lymph
nodes, known as skip metastasis, could develop even in
the early phase of lymphatic invasion in patients with
esophageal carcinoma [4,5,7,8].
The number of metastatic lymph nodes is one of the
most important prognostic factors in esophageal cancer
[9]. The new seventh tumor, node, metastasis (TNM)
staging system reclassified the N stage according to the
number of metastatic lymph nodes [10]. Esophageal car-
cinoma has been regarded as in the earliest lymph node
invasion when only one lymph node is involved [4,8]. It
is important to investigate the prognosis of solitary
lymph node metastasis before the presence of multiple
metastatic nodes, which has already meant systematic
disease and poor prognosis [11]. However, there are few. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Lymph node classification of middle thoracic
carcinoma based on the guidelines of the Japanese
Society for Esophageal Disease (JSED)
Category Numbering Station
N1 108 Middle thoracic paraesophageal
106rec Recurrent nerve
N2 101 Cervical paraesophageal
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metastasis in esophageal cancer.
In this study, the clinical outcomes of 33 patients with
solitary lymph node metastasis in squamous cell carcin-
oma of the middle thoracic esophagus were retrospect-
ively investigated and compared with node-negative (N0)
patients to evaluate the prognostic significance.
Patients and methods
Patients
Between January 2003 and December 2009, a series of
235 patients with middle thoracic esophageal squamous
cell carcinoma underwent curative esophagectomy in
the Department of Thoracic Surgery, Zhejiang Cancer
Hospital, Hangzhou, China. Patients who had a history
of cancer, had a synchronous cancer, or had previously
received chemotherapy or radiotherapy were not included
in this series. Of the 235 patients, 33 had solitary lymph
node metastasis, and 102 patients had no lymph node
metastasis. These 135 patients were analyzed in this retro-
spective study. The institutional review board of Zhejiiang
Cancer Hospital and First Affiliated Hospital, Medical
College, Zhejiang University approved the study and the
need for individual patient consent was waived.
Preoperative evaluation
All patients had endoscopy with biopsy, barium swallow
examination, computed tomography of the chest and
upper abdomen, and ultrasound of the neck. Patho-
logical diagnosis of squamous cell carcinoma was con-
firmed before the operation. Pulmonary and cardiac
function testing were routinely performed to assess med-
ical operability. Tumor location was defined according
to the 6th edition of the American Joint Commission on
Cancer (AJCC) Cancer Staging Manual [12]. Recurrent
laryngeal nerve palsy and the presence of clinical supra-
clavicular or cervical nodal involvement were considered
a contraindication for surgery. The patients underwent
surgery after completing the preoperative evaluation and
providing written informed consent.
Surgical procedure
In our institute, two types of lymphadenectomy were
carried out as a standard procedure for middle thoracic
esophageal cancer. The choice of lymphadenectomy
depended on the surgeon’s preference. Four surgeons
performed two-field lymphadenectomy while two per-
formed three-field lymphadenecotmy. The surgical indi-
cation was the same for operations using these two types
of lymphadenectomy.
All patients underwent right transthoracic esophagect-
omy with either two- or three-field lymphadenectomy.
In principle, two-field lymphadenectomy included total
mediastinal and upper abdominal lymphadenectomy.Three-field lymphadenectomy added resection of cervical
paratracheal, cervical paraesphageal and supraclavicular
lymph nodes to two-field lymphadenectomy. Gastro-
intestinal reconstruction was achieved by stomach bypass
through the posterior mediastinal route and anastomosis
was performed in the neck for all patients. After surgery,
all removed nodes were labeled by their anatomical loca-
tions by the operating surgeon.
Definition of skip metastasis
Three criteria were taken to define skip metastasis as
follows: 1. Lymph node classification based on the
guidelines of the Japanese Society for Esophageal Disease
(JSED), which divides the locations of lymph node me-
tastases into four categories (N1 through N4) [13]. Skip
metastasis was diagnosed when solitary lymph node
metastasis was observed in N2, N3 or N4 beyond N1.
For a middle thoracic tumor, skip metastasis was defined
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other than 106rec and 108 (Table 1). 2. Lymph node
classification based on the 6th edition of the AJCC Can-
cer Staging Manual [12], which numbers the location of
lymph node metastasis. For a middle thoracic tumor,
skip metastasis was defined when solitary lymph node
metastasis was observed in the upper mediastinum,
upper abdomen and neck, that is, metastatic lymph node
that occurred in any locations other than station 5
through 10 (Table 2). 3. Lymph node classification
based on the anatomical compartment. Skip metastasis
was diagnosed when a solitary lymph node metastasis
was observed in the abdomen and neck rather than in
the mediastinum.Follow-up
In general, a follow-up examination was performed in
our outpatient department every 3 months for the first
2 years and 6 months thereafter. The routine follow-up
examination included a physical and routine blood
examinations, blood chemistry, measurement of tumor
markers (carcinoembryonic antigen, squamous cell car-
cinoma antigen), radiograph of the chest, and ultra-
sound. Computed tomography of the chest and upper
abdomen were done every 6 months. Endoscopy wasTable 2 Lymph node classification of middle thoracic
carcinoma based on AJCC
Region Numbering Station
Middle and lower mediastinum 7 Subcarinal
8 M Middle paraesophageal
8 L Lower paraesophageal
9 Pulmonary ligament
10R Right tracheobronchial
10 L Left tracheobronchial
15 Diaphragmatic
Upper mediastinum 2R Right upper paratracheal
2 L Left upper paratracheal
3P Posterior mediastinal
4R Right lower paratracheal








20 Celiacdone yearly. Complete follow-up information until death
or March 2012 was available for all patients.
Statistical analysis
The distribution of continuous variables was described
with the median and range. Categorical variables were
compared between groups using the chi-square test and
Fisher’s exact test if necessary. Survival curves were
constructed by the Kaplan-Meier method [14] and the
log-rank test [15] was used to determine significance.
Significant variables identified by univariate analyses
were assessed by multivariate analyses using Cox’s pro-
portional hazard model [16]. A backward method was
used to eliminate insignificant variables. P- values less
than 0.05 were considered statistically significant.
Results
Comparison of clinicopathological characteristics between
patients with solitary lymph node metastasis and patients
with no lymph node metastasis (N0)
Clinicopathological characteristics of these 135 patients
with N0 or solitary lymph node metastasis are listed in
Table 3. In patients with solitary lymph node metastasis,
advanced tumors (T3) were significantly more common
than in N0 patients. There was no significant difference
in any other variables between these two groups. How-
ever, if the same comparison was made among the entire
235 patients, who were divided into three groups includ-
ing N0 patients, patients with solitary lymph node me-
tastasis and patients with more than one lymph node
metastasis, all variables except age and sex were signifi-
cantly different among the three groups. Tumor
length > 5 cm, G3, T3 and T4 stage and intramural
metastasis were more frequent in patients with more
than one lymph node metastasis than in the other two
groups of patients.
Distribution of solitary lymph node metastasis
The distribution of solitary lymph node metastasis based
on JSED, AJCC and anatomical compartment is sum-
marized in Table 4 and Table 5. Recurrent nerve node
(12 cases) and middle thoracic paraesophageal node (eight
cases) were the most common metastatic sites in solitary
lymph node metastasis. Skip metastasis was shown in
thirteen, twenty-three, and eight patients according JSED,
AJCC and anatomical compartment respectively.
Survival
The 5-year survival rates for N0 patients, patients with
solitary lymph node metastasis and patients with ≥ two
lymph node metastases were 58%, 32%, and 15.9%
respectively (P < 0.001) (Figure 1). There were signifi-
cant differences in survival between N0 patients and
patients with solitary lymph node metastasis (P = 0.008),
Table 3 Comparison of clinicopathological characteristics
between patients with solitary lymph node metastasis
and N0 patients
Characteristic Solitary lymph node
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≤ 5 cm 24 76
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≤ 25 18 59
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≥ two lymph node metastases (P = 0.048), and between
N0 patients and patients with ≥ two lymph node metas-
tasis (P < 0.001).
Patients with solitary lymph node metastasis were fur-
ther analyzed. According to the JSED, the 5-year survival
rates for skip (+) and skip (−) patients were 36% and
29% respectively, both of which were significantly differ-
ent from the 5-year survival for N0 patients (P = 0.047
and P = 0.031 respectively) (Figure 2A). According to
the AJCC, the 5-year survival rates for skip (+) and skip
(−) patients were 37% and 20% respectively. There was a
significant difference in survival between skip (−)
patients and N0 patients (P = 0.004); however, there wasno significant difference in survival between skip (+)
patients and N0 patients (P = 0.094) (Figure 2B).
According to the anatomical compartment, the 5-year
survival rates for skip (+) and skip (−) patients were 58%
and 23% respectively. Survival of Skip (+) patients was
not significantly different from that of N0 patients (P =
0.740). There was a significant difference in survival be-
tween N0 patients and skip (−) patients (P = 0.002)
(Figure 2C).
Univariate and multivariate survival analysis
Univariate survival analysis showed that T category and
N status were significantly associated with prognosis
(Table 6). Multivariate analysis was performed including
T category and N status. Owing to the different criter-
ion of skip metastasis, three models were constructed.
In a model according to the JSED, T category was
the independent prognostic factor. In the other two
models according to the AJCC and anatomical compart-
ment, N status was the independent prognostic factor.
In these two models, however, skip metastasis was not
significantly different from N0 in predicting prognosis
(Table 7).
Discussion
Patients with solitary lymph node metastasis in esopha-
geal cancer has been considered a distinct prognostic
subgroup with cancer outcomes closer to node-negative
disease than any other node-positive subgroup [17]. It
has even been believed that there is no difference in sur-
vival between patients with solitary lymph node metasta-
sis and N0 patients with esophageal squamous cell
carcinoma, and that solitary lymph node metastasis does
not affect the prognosis [5]. In this report, except for T
category, all clinicopathological variables did not differ
between N0 patients and patients with solitary lymph
node metastasis. Solitary lymph node metastasis had a
worse survival compared with N0 disease. These results
may partly explained by the fact that a majority of
patients with solitary lymph node metastasis were at the
T3-stage. But skip metastasis was not a risk factor for
poor prognosis. According to the JSED criterion both
skip (+) and skip (−) patients showed worse survival
than N0 patients, but it was T category not N status that
was the independent prognostic factor in multivariate
analysis. Although N status was the independent prog-
nostic factor according to the other two criteria, there
was still no significant difference between N0 and skip
metastasis in predicting prognosis.
The prognostic impact of lymph node skip meta-
stasis in esophageal carcinoma has been unclear. Some
reports have shown a favorable prognosis of skip metas-
tasis (compared with adjacent or continuous lymph
node metastasis) and others have not [7,18]. Prenzel
Table 4 Distribution of solitary lymph node metastasis
in 33 patients based on the guidelines of the Japanese
Society for Esophageal Disease (JSED) compared with
the American Joint Commission on Cancer (AJCC)
AJCC
Skip (−) (n = 10) Skip (+) (n = 23)
7 8 M 8 L 2R 2 L 3P 4 16 17 1
JSED - - - - - - - - - -
Skip (−) (n = 20) - - - - - - - - - -
106recR - - - 10 - - - - - -
106recL - - - - 2 - - - - -
108 - 8 - - - - - - - -
Skip (+) (n = 13) -
105 - - - - - 2 - - - -
107 1 - - - - - - - - -
110 - - 1 - - - - - - -
1 - - - - - - - 2 - -
2 - - - - - - - 1 - -
3 - - - - - - - - 1 -
7 - - - - - - - - 2 -
104R - - - - - - - - - 1
104 L - - - - - - - - - 1





102 94 83 67 55 44 32 23 11 6
1 (n=33) 33 26 20 15 12 9 6 4 3 1
2 (n=100) 100 63 40 23 15 8 5 5 3 0
Figure 1 Survival curves in 235 patients according to lymph
node status (P < 0.01). N0 vs. one positive node, P= 0.008; N0 vs.
two or more positive nodes, P< 0.001; one positive node vs. two or
more positive nodes, P= 0.048.
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lymph node classification used to define skip metastasis.
In this series, three criteria were used to define skip
metastasis. Skip metastasis did not show a favorable
prognosis compared with adjacent metastasis. But multi-
variate analysis did show that skip metastasis was not
a prognostic factor, whereas adjacent metastasis was
prognostic in two of the three models. It must be
noted that skip metastasis could be caused by ineffi-
cient histopathologic examination by missing out small
metastasis in positive nodes. In addition, micrometasta-
sis detected by immunohistochemistry in histologically
tumor-free nodes is not a rare event in esophageal can-
cer [6,18]. Natsugoe et al. [6] reported micrometastasis
was found in 33 of 59 patients (55.9%) with esophagealTable 5 Summary of solitary lymph node metastasis in thirty
JSED
Skip (−) (n = 20) Skip (+) (n = 13) Skip (−
upper mediastinum 12 3




JSED, Japanese Society for Esophageal Disease; AJCC, American Joint Commission ocarcinoma, who were diagnosed as N0 by routine histo-
logical examination.
As previous reports have shown [4-6,8], solitary lymph
node metastasis in this report was widely distributed,
but was mainly limited to the recurrent nerve region
and middle thoracic paraesophagus region. It was
reasonable that the JSED classified these two regions as
N1 in middle thoracic squamous cell carcinoma. Some
authors have found that solitary lymph node metastasis
in esophageal carcinoma is predominately located in the
abdomen along the lesser curvature and the left gastric
artery [2]. But their series included lower thoracic
tumors and upper mediastinal lymphadenectomy was
not routinely performed. The wide distribution of soli-
tary lymph node metastasis was closely associated with
the tumor site and unique features of lymphatic spread
from the esophagus, which has been discussed in many-three patients defined by three criteria
AJCC Anatomy









N0(n=102) 102 94 83 67 55 44 32 23 11 6
Skip(+) 
(n=13)
13 11 8 4 3 3 2 2 1 0
Skip(-) 
(n=20)
20 15 12 11 8 5 4 2 2 1
Patients  at 
risk
N0(n=102) 102 94 83 67 55 44 32 23 11 6
Skip(+) 
(n=23)
23 18 15 10 9 7 4 3 2 1
Skip(-) 
(n=10)
10 8 5 5 3 2 2 1 1 0
Patients  at 
risk
N0(n=102) 102 94 83 67 55 44 32 23 11 6
Skip(+) 
(n=8)
8 7 7 4 4 4 2 2 1 0
Skip(-) 
(n=25)
25 19 13 11 8 5 4 2 2 1
A B
C
Figure 2 Survival curves in patients with no metastases (N0 patients), patients with skip metastasis, and patients without skip
metastasis according to different criteria. (A) JSED (N0 vs. skip (+), P = 0.047; N0 vs. skip (−), P = 0.031; skip (+) vs. skip (−), P = 0.302).
(B) Survival curves in N0 patients, patients with skip metastasis, and patients without skip metastasis according to AJCC (N0 vs. skip (+), P = 0.094);
N0 vs. skip (−), P= 0.004; skip (+) vs. skip (−), P = 0.302). (C) Survival curves in N0 patients, patients with skip metastasis, and patients without skip
metastasis according to the anatomical compartment (N0 vs. skip (+), P = 0.74; N0 vs. skip (−), P= 0.002; skip (+) vs. skip (−), P = 0.180).
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Table 6 Univariate analysis of survival in 135 patients with squamous cell carcinoma of the middle thoracic esophagus
Variable Number of patients 5-year survival rate Median survival (months) P-value
Age (years) 0.939
≤ 60 87 51% 63
> 60 48 52% 61
Sex 0.500
Female 26 48% 63
Male 169 52% 60
Tumor length 0.903
≤ 5 cm 100 51% 63
> 5 cm 35 50% 88
Differentiation 0.553
G1 38 59% 74
G2 81 48% 59
G3 16 49% 60
T category 0.041
T1 30 67% 86
T2 26 55% 77
T3 79 44% 45
Intramural metastasis 0.135
No 131 52% 63
Yes 4 25% 29
Number of dissected lymph nodes
≤ 25 77 53% 66 0.929
> 25 58 48% 60
Lymphadenectomy 0.206
2-field 110 48% 60
3-field 25 66% 87
N
Negative 102 58% 74 0.008
Positive 33 32% 34
Wu et al. World Journal of Surgical Oncology 2012, 10:210 Page 7 of 9
http://www.wjso.com/content/10/1/210previous reports [4,5,8,19,20]. In addition, middle thor-
acic tumors have a more obvious tendency to develop
bidirectional metastasis than upper and lower thoracic
tumors of the esophagus [1,19,20], so it is still hard to
predict the location of solitary lymph node metastasis,
even if sentinel navigation surgery is used [4].
Three-field might be more appropriate than two-field
lymphadenectomy for middle thoracic esophageal squa-
mous cell carcinoma in terms of the wide distribution of
solitary lymph node metastasis. But there was no survival
difference between patients treated with these two types of
lymphadenectomies (data not shown). Many similar
results reported earlier have also been summarized in
reviews of the literature [21,22]. So far, controversy exists
as to the extent of lymphadenectomy required inesophageal cancer. There is no doubt that more exten-
sive lymphadenectomy provides more accurate nodal
staging [21], but whether it improves survival still
needs to be tested in well-designed randomized con-
trolled trials [22].
Several potential shortcomings in this retrospective
study deserve attention. Surgeons chose different types
of lymphadenectomy depending on their preferences.
A certain selection bias can therefore not be excluded. It
is also possible that variation in the quality of lymphade-
nectomy among different surgeons may interfere with
the results. In addition, the sample size was limited by
nature of the single institution of the study. Validation
from other institutions is needed. Nonetheless, this
series proved to be homogenous with regard to many
Table 7 Multivariate analysis of survival in 135 patients
with squamous cell carcinoma of the middle thoracic
esophagus




T2 1.442 0.685, 3.033 0.335
T3 2.060 1.126, 3.769 0.019
N 0.185
N0 (reference) 1
Skip (+) 1.586 0.780, 3.223 0.203




T2 1.474 0.700, 3.105 0.308
T3 1.768 0.943, 3.317 0.076
N 0.013
N0 (reference) 1
Skip (+) 1.591 0.915, 2.769 0.100




T2 1.517 0.720, 3.918 0.273
T3 1.843 0.988, 3.433 0.055
N 0.010
N0 (reference) 1
Skip (+) 1.145 0.458, 2.860 0.772
Skip (−) 2.178 1.320, 3.593 0.002
JSED, Japanese Society for Esophageal Disease; AJCC, American Joint
Commission on Cancer; CI, confidence interval.
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and preoperative management.
Conclusions
For patients with middle thoracic esophageal squamous
cell carcinoma, solitary lymph node metastasis has a
negative impact on survival compared with N0 disease;
skip metastasis, however, is comparable to N0 disease in
predicting prognosis.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JW conceived this study, collected data, performed analysis and drafted the
manuscript. QXC participated in study design, literature search and
coordination. JW, QXC, XMZ and WMM participated in the treatment of
these patients. MJK performed data analysis and helped to draft themanuscript. LST participated in study design and helped to draft the
manuscript. All authors read and approve the final manuscript.
Author details
1Department of Surgical Oncology, First Affiliated Hospital, Zhejiang
University School of Medicine, 79 Qingchun Road, Hangzhou 310033, China.
2Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou
310022, China. 3Meridian Cancer Care, Jersey Shore University Medical
Center, Neptune, NJ 07753, USA.
Received: 12 August 2012 Accepted: 18 September 2012
Published: 4 October 2012References
1. Chen J, Liu S, Pan J, Zheng X, Zhu K, Zhu J, Xiao J, Ying M: The pattern and
prevalence of lymphatic spread in thoracic oesophageal squamous cell
carcinoma. Eur J Cardiothorac Surg 2009, 36:480–486.
2. Schröder W, Prenzel K, Baldus SE, Mönig SP, Schneider PM, Hölscher AH:
Localization of isolated lymph node metastases in esophageal
cancer–does it influence the sentinel node concept?
Hepatogastroenterology 2007, 54:1116–1120.
3. Takeuchi H, Fujii H, Ando N, Ozawa S, Saikawa Y, Suda K, Oyama T, Mukai M,
Nakahara T, Kubo A, Kitajima M, Kitagawa Y: Validation study of radio-
guided sentinel lymph node navigation in esophageal cancer. Ann Surg
2009, 249:757–763.
4. Matsubara T, Ueda M, Kaisaki S, Kuroda J, Uchida C, Kokudo N, Takahashi T,
Nakajima T, Yanagisawa A: Localization of initial lymph node metastasis
from carcinoma of the thoracic esophagus. Cancer 2000, 89:1869–1873.
5. Kunisaki C, Makino H, Kimura J, Oshima T, Fujii S, Takagawa R, Kosaka T,
Ono H, Akiyama H, Endo I: Therapeutic strategy for esophageal cancer
based on solitary lymph node metastasis. Hepatogastroenterology 2011,
58:1561–1565.
6. Natsugoe S, Matsumoto M, Okumura H, Nakashima S, Higashi H,
Uenosono Y, Ehi K, Ishigami S, Takao S, Aikou T: Initial metastatic, including
micrometastatic, sites of lymph nodes in esophageal squamous cell
carcinoma. J Surg Oncol 2005, 89:6–11.
7. Prenzel KL, Bollschweiler E, Schröder W, Mönig SP, Drebber U, Vallboehmer D,
Hölscher AH: Prognostic relevance of skip metastases in esophageal cancer.
Ann Thorac Surg 2010, 90:1662–1667.
8. Shimada H, Okazumi S, Matsubara H, Nabeya Y, Shiratori T, Shuto K,
Shimizu T, Akutsu Y, Tanizawa Y, Hayashi H, Ochiai T: Location and clinical
impact of solitary lymph node metastasis in patients with thoracic
esophageal carcinoma. Am J Surg 2006, 192:306–310.
9. Lin CS, Chang SC, Wei YH, Chou TY, Wu YC, Lin HC, Wang LS, Hsu WH:
Prognostic variables in thoracic esophageal squamous cell carcinoma.
Ann Thorac Surg 2009, 87:1056–1065.
10. Rice TW, Blackstone EH, Rusch VW: 7th edition of the AJCC Cancer Staging
Manual: esophagus and esophagogastric junction. Ann Surg Oncol 2010,
17:1721–1724.
11. Peyre CG, Hagen JA, DeMeester SR, Van Lanschot JJ, Hölscher A, Law S,
Ruol A, Ancona E, Griffin SM, Altorki NK, Rice TW, Wong J, Lerut T,
DeMeester TR: Predicting systemic disease in patients with esophageal
cancer after esophagectomy: a multinational study on the significance
of the number of involved lymph nodes. Ann Surg 2008, 248:979985.
12. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th
edition. Philadelphia: Lippincott-Raven; 2002.
13. Japanese Society for Esophageal Diseases: Guidelines for Clinical and
Pathologic Studies on Carcinoma of the Esophagus. Tokyo: Kanehara & Co,
Ltd: 9th edition; 2001.
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete
observations. J Am Stat Assoc 1958, 53:457–481.
15. Peto R: Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N,
McPherson K, Peto J. Smith PG: Design and analysis of randomized clinical
trials requiring prolonged observation of each patient. II. analysis and
examples. Br J Cancer 1977, 35:1–39.
16. Cox DR: Statistical significance tests. Br J Clin Pharmacol 1982, 14:325–331.
17. O'Riordan JM, Rowley S, Murphy JO, Ravi N, Byrne PJ, Reynolds JV: Impact
of solitary involved lymph node on outcome in localized cancer of the
esophagus and esophagogastric junction. J Gastrointest Surg 2007,
11:493–499.
Wu et al. World Journal of Surgical Oncology 2012, 10:210 Page 9 of 9
http://www.wjso.com/content/10/1/21018. Hosch SB, Stoecklein NH, Pichlmeier U, Rehders A, Scheunemann P,
Niendorf A, Knoefel WT, Izbicki JR: Esophageal cancer: the mode of
lymphatic tumor cell spread and its prognostic significance. J Clin Oncol
2001, 19:1970–1975.
19. Tachimori Y, Nagai Y, Kanamori N, Hokamura N, Igaki H: Pattern of lymph
node metastases of esophageal squamous cell carcinoma based on the
anatomical lymphatic drainage system. Dis Esophagus 2011, 24:33–38.
20. Motoyama S, Maruyama K, Sato Y, Usami S, Nakatsu T, Saito H, Minamiya Y,
Ogawa J: Status of involved lymph nodes and direction of metastatic
lymphatic flow between submucosal and T2-4 thoracic squamous cell
esophageal cancers. World J Surg 2009, 33:512–517.
21. Darling G: The role of lymphadenectomy in esophageal cancer. J Surg
Oncol 2009, 99:189–193.
22. Jamieson GG, Lamb PJ, Thompson SK: The role of lymphadenectomy in
esophageal cancer. Ann Surg 2009, 250:206–209.
doi:10.1186/1477-7819-10-210
Cite this article as: Wu et al.: Prognostic significance of solitary lymph
node metastasis in patients with squamous cell carcinoma of middle
thoracic esophagus. World Journal of Surgical Oncology 2012 10:210.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
